KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. Continued Leading Sponsorship at 2024 EPOSNA Annual Meeting

OrthoPediatrics Corp. Continued Leading Sponsorship at 2024 EPOSNA Annual Meeting

Reinforced Long-Term Commitment as Emerald Sponsor

WARSAW, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support of the combined 2024 Pediatric Orthopaedic Society of North America (“POSNA”) and European Paediatric Orthopaedic Society (“EPOS”) annual meeting as an Emerald sponsor.

At the Annual Meeting, the Company highlighted its growing portfolio of pediatric-specific solutions at its exhibit booth. The Company sponsored a session focused on decision-making in the orthopedic management of neuromuscular patients led by physicians from Boston Children’s, Nemours Children’s Health, and Hôpital Robert Debré. This session covered the orthopedic issues patients and surgeons face throughout the pediatric lifespan, including hip subluxation and dislocation, deformity correction, and scoliosis with an emphasis on both non-operative and operative care, early intervention, pre-operative planning, and the multiple decision points that the surgeon will encounter.

OrthoPediatrics has established a long-term commitment to POSNA and EPOS providing ongoing support of specialty symposiums and awarding educational grants and scholarships to attendees. The Company was the only Emerald Sponsor of the meeting.

OrthoPediatrics’ President & CEO, David Bailey, commented, “We were very excited to continue our commitment to POSNA and reinforce our long-standing collaboration with the prestigious society. OrthoPediatrics is completely aligned with the POSNA and EPOS organizations in our efforts to advance the field of pediatric orthopedics. It was extremely productive to spend time among the many thought leaders in attendance and humbling to hear how OrthoPediatrics’ products are helping treat more kids. I would like to thank everyone who participated in making this the marquee meeting of the year for our field.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 71 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit

Investor Contact

Philip Trip Taylor

Gilmartin Group



415-937-5406



EN
15/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics to Participate in Upcoming Conferences

OrthoPediatrics to Participate in Upcoming Conferences WARSAW, Ind., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it will participate in two upcoming investor conferences. Event: TD Cowen 46th Annual Health Care Conference Format: Fireside Chat Date: Tuesday, March 3, 2026Time: 1:10 pm ET Event: The Citizens Life Sciences Conference Format: Fireside Chat Date: Tuesday, March 10, 2026Time: 10:10 am ET An audio webcast of the ...

 PRESS RELEASE

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financ...

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results Record full year 2025 revenue of $236.3 million increased 15% compared to prior yearOperating Cash flow improvement of $22 million in full year 2025Generated $10 million of free cash flow in the fourth quarter, the first quarter of positive free cash flow in Company history WARSAW, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial resu...

 PRESS RELEASE

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Fina...

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. OrthoPediatrics will host a conference call on Thursday, February 26, 2026 at 4:30 p.m. ET to discuss the results. Inv...

 PRESS RELEASE

OrthoPediatrics Announces Expanded Enabling Technology Market Opportun...

OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older WARSAW, Ind., Feb. 03, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its partner, iotaMotion, has received FDA 510(k) clearance for expanded pediatric use of its iotaSOFT® Insertion System. The system is now cleared for ...

 PRESS RELEASE

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue fo...

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance Achieves all-time high full year 2025 Revenue of $236.1 million representing growth of 15% over prior yearInitiates guidance for record Adjusted EBITDA in 2026 WARSAW, Ind., Jan. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended December...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch